Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223533 | 1.00 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL7428637 | 0.97 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL984 | 0.90 | HTR2A (0.54) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL13324130 | 0.89 | TP53 (0.46) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL23537658 | 0.83 | BUB1 (0.43) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL29824768 | 0.83 | BUB1 (0.43) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL6755499 | 0.80 | HDAC1 (0.56) | KDM4EMAPK1HSD17B10TP53CREBBP | |
| SCHEMBL10666131 | 0.80 | HDAC1 (0.50) | KDM4EHDAC1HDAC6ALDH1A1 | |
| SCHEMBL22708510 | 0.80 | TP53 (0.46) | KDM4EHSD17B10TP53CREBBPHDAC1 | |
| SCHEMBL15723838 | 0.80 | CSNK2B (0.58) | MAPK1TP53CREBBPHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677560-B | Synthesis method of 1,2,3, 9-tetrahydro-9-methyl-4H-carbazole-4-one | 常州兰陵制药有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | claimed |
| EP-1828141-A4 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LAB LTD (IN) | 2009-04-01 | — | — | EP | claimed |
| EP-1828141-A1 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| WO-2006046253-A1 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | WO | claimed |
| US-20060041004-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2006-02-23 | — | — | US | claimed |
| WO-2006018846-A2 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-METHYLENE-4H- CARBAZOL-4-ONE AND ONDANSETRON THEREFROM | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-23 | — | — | WO | claimed |
| US-20020061919-A1 | PROCESS FOR THE PREPARATION OF 1,2,3,9-TETRAHYDRO-9-METHYL-3-{(2-METHYL-1H-IMIDAZOL-1-YL)METHYL}-4H-CARBAZOL-4-ONE | HANMI PHARM. CO., LTD. (KR) | 2002-05-23 | — | — | US | claimed |
| EP-1207160-A1 | Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one | Hanmi Pharm. Co., Ltd. (KR) | 2002-05-22 | — | — | EP | claimed |
| US-6388091-B1 | IN PRESENCE OF A HALOSILANE COMPOUND; CRYSTALLIZATION, PURIFICATION | HANMI PHARM. CO., LTD. (KR) | 2002-05-14 | — | — | US | claimed |
| CN-115677560-B | Synthesis method of 1,2,3, 9-tetrahydro-9-methyl-4H-carbazole-4-one | 常州兰陵制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115677560-B | Synthesis method of 1,2,3, 9-tetrahydro-9-methyl-4H-carbazole-4-one | 常州兰陵制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115677560-B | Synthesis method of 1,2,3, 9-tetrahydro-9-methyl-4H-carbazole-4-one | 常州兰陵制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111100061-B | Novel carbazole compound, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3820845-B1 | NOVEL, NEW GENERATION INHIBITOR COMPOUNDS SPECIFIC TO GST P1 ENZYME | HACETTEPE UENIVERSITESI (TR) | 2023-05-24 | — | — | EP | disclosed |
| US-5416221-A | ONDANSETRON INTERMEDIATES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-05-16 | — | — | US | disclosed |
| EP-0595111-A1 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1994-05-04 | — | — | EP | disclosed |
| US-5202343-A | Treating anxiety, psychological disorders | GLAXO GROUP LIMITED (GB) | 1993-04-13 | — | — | US | disclosed |
| US-4859662-A | Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances | GLAXO GROUP LIMITED (GB) | 1989-08-22 | — | — | US | disclosed |
| US-4822881-A | PSYCHOTIC DISORDERS, ANXIETY, NAUSEA, VOMITING | GLAXO GROUP LIMITED | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061919-A1 | PROCESS FOR THE PREPARATION OF 1,2,3,9-TETRAHYDRO-9-METHYL-3-{(2-METHYL-1H-IMIDAZOL-1-YL)METHYL}-4H-CARBAZOL-4-ONE | JAK1, CILK1, AZI2 | HTR2A 762/4885HTR2C 141/4885KDM4E 549/4885 |
| US-20060041004-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | HTR3A, ADORA3, HTR4 | HTR2A 22/4885HTR2C 10/4885KDM4E 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.